Kristina Burow and Paul Berns, Neumora
October 7, 2021 06:30 AM EDTUpdated June 29, 02:30 PM
Financing
Startups

ARCH un­veils its Re­al­ly Big Neu­ro­science Com­pa­ny with $500M, an Am­gen deal and eyes on de­pres­sion, Alzheimer's and a lot more

Jason Mast

Editor

ARCH Ven­ture is dou­bling — and tripling and qua­dru­pling — down on the be­lief that the 2020s will be neu­ro­science’s decade.

The VC firm, known for pe­ri­od­i­cal­ly …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Among phar­ma CEOs, the IRA now and the IRA lat­er get very dif­fer­ent re­ac­tions

Up­dat­ed: With cost-cut­ting un­der­way, Bris­tol My­ers rais­es guid­ance, touts Phase 3 win and scraps an­oth­er

Bris­tol My­ers restarts ra­dio­phar­ma­ceu­ti­cal Phase 3 tri­al, but de­lays read­out by one year

An­drew Left, short sell­er who cam­paigned against Valeant, is ac­cused of fraud by SEC

Eu­ro­pean drug reg­u­la­tor re­jects Alzheimer's drug Leqem­bi, cit­ing safe­ty con­cerns

sponsored

Crit­i­cal Junc­tures in Gene Ther­a­py Clin­i­cal Ma­te­r­i­al Man­u­fac­tur­ing: Where Do I Start? And Will It Work?

A service from the Financial Times